Drug delivery systems

• US 7,544,371 B2
• Filed: 12/20/2005
• Issued: 06/09/2009
• Est. Priority Date: 12/20/2005
• Status: Expired due to Fees

• Current Assignee: Bausch & Lomb Incorporated (Bausch Health Cos., Inc.)
• Original Assignee: Bausch & Lomb Incorporated (Bausch Health Cos., Inc.)
• Inventors: Salamone, Joseph, Kunzler, Jay
• Primary Examiner(s): Henley, III; Raymond J
• Application Number:
  US11/311,983
• Publication Number:
  US 20070141115A1
• Time in Patent Office: 1,267 Days
• Field of Search: 424/427, 424/486, 424/484
• US Class Current: 424/484
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears

Abstract

Matrix controlled diffusion drug delivery systems based on one or more silicone-containing monomers of the general formula:

wherein x, y, m, m′, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, X, Z and Z′ are as defined herein are provided, wherein the matrix controlled diffusion drug delivery systems are sized and configured for back of the eye delivery.

Claims

1. A matrix controlled diffusion drug delivery system comprising a therapeutically effective amount of one or more pharmaceutically active agents entrapped in a polymerization product of a monomeric mixture comprising one or more silicone-containing monomers of the general formula:

2. The matrix controlled diffusion drug delivery system of claim 1, wherein x is 2 to about 100, y is 2 to about 100, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are independently a straight or branched C₁-C₃₀ alkyl group, and Z and Z′

are selected from an ester or amide of acrylic or methacrylic acid.

3. The matrix controlled diffusion drug delivery system of claim 1, wherein x is 2 to about 100, y is 2 to about 100, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are independently a straight or branched C₁-C₆ alkyl group X is a bond or an ether or polyether containing group, and Z and Z′

are independently an ester or amide of acrylic or methacrylic acid.

4. The matrix controlled diffusion drug delivery system of claim 1, wherein x is 2 to about 100, y is 2 to about 100, R is independently a straight or branched C₁-C₃₀ fluoroalkyl group, an alkyl ether or polyether group or a straight or branched C ₁-C₃₀ alkylamide group, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are independently a straight or branched C₁-C₆ alkyl group, X is independently a bond or one or more C₁-C₃₀ alkyl ether groups or polyether groups and Z and Z′

are independently an ester or amide of acrylic or methacrylic acid.

5. The matrix controlled diffusion drug delivery system of claim 1, wherein the one or more pharmaceutically active agents is selected from the group consisting of an anti-glaucoma agent, anti-cataract agent, anti-diabetic retinopathy agent, thiol cross-linking agent, anti-cancer agent, immune modulator agent, anti-clotting agent, anti-tissue damage agent, anti-inflammatory agent, anti-fibrous agent, non-steroidal anti-inflammatory agent, antibiotic, anti-pathogen agent, piperazine derivative, cycloplegic agent, miotic agent, mydriatic agent and mixtures thereof.

6. The matrix controlled diffusion drug delivery system of claim 1, wherein the one or more pharmaceutically active agents is selected from the group consisting of an anticholinergic, anticoagulant, antifibrinolytic, antihistamine, antimalarial, antitoxin, chelating agent, hormone, immunosuppressive, thrombolytic, vitamin, protein, salt, desensitizer, prostaglandin, amino acid, metabolite, antiallergenic and mixtures thereof.

7. The matrix controlled diffusion drug delivery system of claim 1, wherein the monomeric mixture comprises one or more other monomers or prepolymers.

8. The matrix controlled diffusion drug delivery system of claim 7, wherein the one or more monomers are selected from the group consisting of methyl methacrylate, 2-ethylhexyl methacrylate, benzyl methacrylate, 2-phenylethyl methacrylate, dimethyl itaconate, trifluoromethyl methacrylate, hexafluoroisopropyl methacrylate, bis(hexafluoroisopropyl) methacrylate, 2-hydroxyethyl methacrylate, hydroxyethoxyethyl methacrylate, hydroxydiethoxyethyl methacrylate, methoxyethyl methacrylate, methoxyethoxyethyl methacrylate, methoxydiethoxyethyl methacrylate, poly(ethylene glycol) methacrylate, methoxy-poly(ethylene glycol) methacrylate, methacrylic acid, acrylic acid, itaconic acid, acrylic anhydride, methacrylic anhydride, maleic anhydride, itaconic anhydride, glycerol methacrylate, hydroxypropyl methacrylate, N,N-dimethylacrylamide, acrylamide, N-methylacrylamide, N-vinylpyrrolidione, N-isopropylacrylamide, hydroxybutyl methacrylate and mixtures thereof.

9. The matrix controlled diffusion drug delivery system of claim 1, in a form of a solution, suspension, solution/suspension, microsphere or nanosphere.

10. The matrix controlled diffusion drug delivery system of claim 1, in a form of a semi-solid or solid article suitable for ocular implant.